Efimosfermin Alfa

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Alcoholic Fatty Liver DiseaseHepatic Impairment

31 competitors in Non-Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

1

Actos

Takeda

Approved

62

Avandia

Jazz Pharmaceuticals

Approved

13

Crestor

AstraZeneca

Approved

—4

Bayer Aspirin

Bayer

Approved

—5

Actigall

AbbVie

Approved

—6

Calciferol

Jazz Pharmaceuticals

Approved

—7

Uloric

Takeda

Approved

—8

Januvia

ZZydus Therapeutics Inc.

Approved

39

Jardiance

Boehringer Ingelheim

Approved

210

Glucophage

EMD Serono

Approved

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease3 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Recruiting·GSK·Phase 3·NCT07221188·1,250 enrolled

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Completed·GSK·Phase 1·NCT07335198·30 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Recruiting·GSK·Phase 3·NCT07221227·1,200 enrolled

Metabolic Dysfunction-associated Steatohepatitis2 trials

A Phase 3, Two-part, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis (Stage F4 Fibrosis) Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-2)

Recruiting·GSK·Phase 3·NCT07704892·380 enrolled

A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)

Recruiting·GSK·Phase 3·NCT07701993·1,740 enrolled

Hepatic Impairment1 trial

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Not yet recruiting·GSK·Phase 1·NCT07358546·32 enrolled

Liver1 trial

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)

Recruiting·GSK·Phase 2·NCT07791043·274 enrolled

Details

Drug Info

Related News